Composition and method for treating cognitive impairments in down syndrom subjects
US9078874B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2010 |
| Grant date | Jul 14, 2015 |
| Priority date | — |
| Expiry date | Nov 21, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds having inverse agonist functional selectivity for GABAA receptors containing the α5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.